Ocuphire Q2 net loss $7.8M ($0.30/sh); cash $41.4M; VEGA-3 recruiting for presbyopia

Opus Genetics, Inc.

2024-Q2 EPS reported -$0.59 revenue$2,823,000

Net loss $7.8M ($0.30/sh) vs $5.0M ($0.24) in Q2 2023; revenue from collaborator license $1.1M vs $3.7M.
Cash $41.4M provides runway into mid-2025; R&D spend $6.1M (+30% YoY) driven by APX3330 manufacturing.
VEGA-3 Phase 3 trial of phentolamine ophthalmic solution 0.75% for presbyopia now recruiting; topline 2025.
LYNX-2 Phase 3 study for dim light disturbances enrollment strong; LYNX-3 study planned for 2024.
Discussions with FDA ongoing for APX3330 Special Protocol Assessment in diabetic retinopathy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.